PURPOSE: Given the nature of oncology trial design and conduct, overall survival effects of treatments are often not directly measured. However, estimates of these survival effects are important for economic evaluation. This workshop was constructed to provide those interested in this area a selection of recent research efforts that address this issue. DESCRIPTION: The four papers in this session reflect separate studies on various aspects of estimating or modeling overall survival effects in oncology treatment. Topics include parametric and simulation modeling tailored to mechanism of action, use of registry data for background survival estimation, adjusting for varying follow-up times and sample sizes, integrated survival modeling across treatments, and applications to cost-effectiveness and budget impact modeling. PROJECTING SURVIVAL WITH IMMUNO-ONCOLOGY THERAPIES Jack Ishak, PhD, Senior Research Leader, Modeling & Simulation, Evidera, Montreal, QC, Canada; Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, United Kingdom; Irina Proskorovsky, MSc, Director, Principal Statistician, Modeling & Simulation, Evidera, Montreal, QC, Canada; Yiduo Zhang, PhD, Director, Health Economics and Payer Analytics, Astrazeneca, Gaithersburg, MD, USA MODELING LONG-TERM SURVIVAL AND ECONOMIC IMPLICATIONS IN TARGETED CANCER THERAPIES Federico Felizzi, PhD, HTA Statistician, GPMA, F. Hoffmann La Roche, Basel, Switzerland; Anirban Basu, PhD, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA; Aasthaa Bansal, PhD, Research Assistant Professor, Pharmaceutical Outcomes Research & Policy Program, University of Washington, Seattle, WA, USA; Noman Paracha, MSc, Health Economist, GPMA, F. Hoffman-La Roche, Basel, Switzerland MODELING SURVIVAL EXPERIENCE USING REAL WORLD EVIDENCE: INSIGHTS FOR CLINICAL TRIAL-BASED ECONOMIC EVALUATIONS Andy Briggs, PhD, William R. Lindsey Chair, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom; Dhvani Shah, MS, Senior Health Economist, Health Economics, ICON Plc, New York, NY, USA; Victoria Federico Paly, MHS, Senior Health Economist, ICON Health Economics & Epidemiology, New York City, NY, USA; Vijayveer Bonthapally, PhD, Senior Director, Formerly Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA USING SURVIVAL ANALYSES TO DEVELOP FLEXIBLE BUDGET IMPACT MODELS IN ONCOLOGY Keith R Abrams, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, United Kingdom; Aline Gauthier, MSC, Managing Director, Health Economics and Market Access, Amaris, London, United Kingdom; Emanuela Castelnuovo, MSc, MA, Director, Health Economics and Market Access, Amaris, London, United Kingdom